Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Pembrolizumab biosimilar by Bio-Thera Solutions for Solid Tumor: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Phase I for Solid Tumor. According to GlobalData,...
BAT-8006 by Bio-Thera Solutions for Epithelial Ovarian Cancer: Likelihood of Approval
BAT-8006 is under clinical development by Bio-Thera Solutions and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
BAT-8006 by Bio-Thera Solutions for Peritoneal Cancer: Likelihood of Approval
BAT-8006 is under clinical development by Bio-Thera Solutions and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Ustekinumab biosimilar by Bio-Thera Solutions for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
Ustekinumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to...
Bevacizumab biosimilar by Bio-Thera Solutions for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According...
BAT-4406F by Bio-Thera Solutions for Autoimmune Disorders: Likelihood of Approval
BAT-4406F is under clinical development by Bio-Thera Solutions and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase...